MassDevice

Johnson & Johnson study backs Abiomed Impella 5.5 in non-shock, high-risk patients

Johnson & Johnson (NYSE:JNJ) today shared new clinical findings from a novel U.S. pilot study of its Abiomed unit’s Impella 5 ...
Nasdaq

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

Several studies show that the use of percutaneous ventricular assist devices (PVADs), including Impella, is particularly cost-effective in cases of cardiogenic shock: Several studies, including ...

Study finds no benefit to miniature heart pump during complex stent procedures

Results from the first randomized trial of Impella pumps during complex stent procedures, published in the New England ...
Business Wire

First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug ...
TCTMD

Longer-Term Data Still Worrisome for Impella-Treated AMICS Patients

Patients undergoing PCI for acute MI complicated by cardiogenic shock (AMICS) had worse outcomes—including more mortality and bleeding—when their hemodynamic support during that hospitalization was ...
Healio

Safety of percutaneous microaxial LVAD for cardiogenic shock uncertain vs. other options

Please provide your email address to receive an email when new articles are posted on . In some analyses, percutaneous microaxial LVAD for cardiogenic shock was tied to worse outcomes vs. medical ...
TCTMD

Percutaneous LVADs Can Spur Aortic Regurgitation, Small Study Cautions

For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...
Business Wire

FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular ...
Healio

Abiomed recalls LVADs for motor damage risk after contact with TAVR stent

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Abiomed announced a recall of its LVAD due to ...
Nasdaq

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

DANVERS, Mass.--(BUSINESS WIRE)-- Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ ...
Medscape

FDA Expands Impella Heart Pumps Use Duration

The US Food and Drug Administration (FDA)-approved labeling for the Impella 5.0 and Impella LD heart pumps (Abiomed) has been expanded to allow for longer support time in critically ill patients, the ...